Telix Pharmaceuticals Recruits patients for renal cancer trial
- Telix Pharmaceuticals (TLX) recruits more than 50 per cent of patients required for its ZIRCON phase three study for imaging renal cancer
- The trial will treat around 250 renal cancer patients undergoing kidney surgery to determine the sensitivity and specificity of its drug, TLX250-CDx
- The study has exceeded enrolment expectations despite reduced numbers over the last twelve months due to COVID-19
- The company Chief Medical Officer Dr Colin Hayward says it’s pleasing to see the trial accelerating and a resumption to normal clinical operating conditions
- The company says it expects the trial to complete recruitment over the next four to five months, subject to ongoing pandemic conditions
